MediPrint Ophthalmics Announces Promising Results from Its SIGHT-2 Phase 2b Group 1 Clinical Study

Logo BenzingaBenzinga
2023-06-09 00:11:00  • 9 mins

Human Trial with Novel Glaucoma Treatment Rendered a Clinically Meaningful Efficacy Outcome and Positive Safety and Tolerability Data

Today, MediPrint Ophthalmics (MediPrint), an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces it has completed its SIGHT-2 dose-finding Phase 2b Group 1 (low dose) study for its proprietary drug-eluting contact lens for glaucoma. This is the first of potentially three doses in the second study of its clinical program SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) for LL-BMT1, a preservative-free weekly medicated contact lens releasing bimatoprost to treat open angle glaucoma and ocular hypertension. SIGHT-2 is designed to assess dose optimization for the Company's lead asset, LL-BMT1, and was preceded by the successful completion of the Company's SIGHT-1 study that validated the MediPrint process and contact lenses for treating human subjects.

In the SIGHT-2 Group 1 study, MediPrint's LL-BMT1 (low dose) was administered to 11 patients, whose average age was 52.0 years old and who had not previously worn contact lenses, for a duration of three (3) weeks. The study subjects wore a new LL-BMT1 (low dose) lens in each eye for seven (7) days continuously for three (3) consecutive weekly lens insertion cycles (21 days total). There was also a reference arm in the clinical trial in which the study subjects used timolol 0.5% topical eye drops twice a day for three (3) weeks.

Continue read on

(RTTNews) - Vigil Neuroscience, Inc. (VIGL) Tuesday said it received positive opinion from EMA's Committee for Orphan Medicinal Products (COMP) for the...
Logo NasdaqNasdaq
2023-09-26 11:50:13  • 1 min
(RTTNews) - Biogen Inc. (BIIB) has completed the acquisition of Reata Pharmaceuticals, Inc. (RETA). As a result, Biogen has now acquired SKYCLARYS, and other...
Logo NasdaqNasdaq
2023-09-26 14:03:36  • 1 min
Despite significant initiatives by generic drug companies to broaden access to vital medicines, many vulnerable patients remain underserved, according to...
Logo BenzingaBenzinga
2023-09-26 14:52:49  • 1 min
(RTTNews) - IDEAYA Biosciences, Inc. (IDYA) said the FDA has granted Fast Track designation to development program investigating IDE161 for the treatment of...
Logo NasdaqNasdaq
2023-09-27 10:29:47  • 1 min
(RTTNews) - Pliant Therapeutics, Inc. (PLRX) reported positive data from INTEGRIS-PSC, a Phase 2a clinical trial of bexotegrast in patients with primary...
Logo NasdaqNasdaq
2023-09-26 12:35:24  • 1 min
(RTTNews) - Immunovant, Inc. (IMVT), a subsidiary of Roivant (ROIV), Tuesday reported positive initial data from the Phase 1 study of its drug candidate...
Logo NasdaqNasdaq
2023-09-26 11:05:05  • 1 min
Health care stocks were leaning lower premarket Tuesday, with the iShares Biotechnology ETF ( IBB ) was marginally declining and the Health Care Select...
Logo NasdaqNasdaq
2023-09-26 13:18:01  • 1 min
(RTTNews) - Ionis Pharmaceuticals Inc. (IONS) announced positive results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia...
Logo NasdaqNasdaq
2023-09-26 11:54:17  • 1 min
(RTTNews) - ZimVie Inc. (ZIMV) announced that on September 7, 2023, the FDA approved its Mobi-C Cervical Disc Hybrid Investigational Device Exemption...
Logo NasdaqNasdaq
2023-09-26 12:45:38  • 1 min
Immunovant Inc IMVT, a unit of Roivant Sciences Ltd ROIV, announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in...
Logo BenzingaBenzinga
2023-09-26 13:33:10  • 1 min
(RTTNews) - Phathom Pharmaceuticals, Inc. (PHAT), a biopharmaceutical company focused on gastrointestinal or GI diseases, announced Tuesday the submission of...
Logo NasdaqNasdaq
2023-09-26 13:05:01  • 1 min
(RTTNews) - Evotec SE (EVO, EVOTF.PK) and Novo Nordisk A/S (NVO) announced Tuesday a translational drug discovery accelerator called LAB eN, which aims to...
Logo NasdaqNasdaq
2023-09-26 12:08:17  • 1 min
Fintel reports that on September 26, 2023, JMP Securities maintained coverage of Benitec Biopharma ( NASDAQ:BNTC ) with a Market Outperform recommendation....
Logo NasdaqNasdaq
2023-09-26 22:31:25  • 1 min
Italy-based Alfasigma has agreed to acquire Intercept Pharmaceuticals Inc ICPT for $19.00 per share in cash. The purchase price represents a premium of 82%...
Logo BenzingaBenzinga
2023-09-26 13:30:10  • 1 min
Shares in biotech firm Oxford BioDynamics (OBD) soared as the firm launched its 'highly accurate' prostate cancer test in the UK and the US. The AIM-listed...
Logo Daily MailDaily Mail
2023-09-27 00:39:15  • 1 min
(RTTNews) - Biopharmaceutical company Theratechnologies Inc. (THTX, TH.TO) announced it has filed a supplemental Biologics License Application (sBLA) for the...
Logo NasdaqNasdaq
2023-09-25 11:21:55  • 1 min
Fintel reports that on September 26, 2023, Mizuho reiterated coverage of Sarepta Therapeutics ( NASDAQ:SRPT ) with a Buy recommendation. Analyst Price...
Logo NasdaqNasdaq
2023-09-26 17:59:09  • 1 min
Fintel reports that on September 26, 2023, Truist Securities reiterated coverage of O-I Glass ( NYSE:OI ) with a Buy recommendation. Analyst Price Forecast...
Logo NasdaqNasdaq
2023-09-27 05:26:44  • 1 min
(RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) announced Monday that the European Commission has granted conditional marketing authorization for TEPKINLY...
Logo NasdaqNasdaq
2023-09-25 12:50:51  • 1 min
(RTTNews) - Liquidia Corporation (LQDA) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's amendment to the...
Logo NasdaqNasdaq
2023-09-25 21:06:21  • 1 min